Pan-Genotypic Hepatitis C Treatment with Glecaprevir and Pibrentasvir for 8 Weeks Resulted in Improved Cardiovascular and Metabolic Outcomes and Stable Renal Function: A Post-Hoc Analysis of Phase 3 Clinical Trials

INTRODUCTION: Chronic hepatitis C (CHC) infection is associated with extrahepatic manifestations (EHMs) which can affect renal, cardiovascular and other comorbidities. The effect of CHC treatment with short-duration regimens on these EHMs is not well defined. Hence, we examined longitudinal estimate...

Descripción completa

Detalles Bibliográficos
Autores principales: Tran, Tram T., Mehta, Darshan, Mensa, Federico, Park, Caroline, Bao, Yanjun, Sanchez Gonzalez, Yuri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249176/
https://www.ncbi.nlm.nih.gov/pubmed/30368684
http://dx.doi.org/10.1007/s40121-018-0218-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249176/
https://www.ncbi.nlm.nih.gov/pubmed/30368684
http://dx.doi.org/10.1007/s40121-018-0218-x

Ejemplares similares